BCL2 and B-cell chronic lymphocytic leukemia: While a stronger cytotoxic agent such as venetoclax33 might have been more effective than DEX, the results reported here suggest addition of ruxolitinib would likely still activate CLL cells (Figure 4) and may cause resistance to BCL2 inhibition.34